Filtered By:
Vaccination: Covid Vaccine
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 1865 results found since Jan 2013.
Telogen effluvium and COVID-19: a cross-sectional study
CONCLUSIONS: In our study, the incidence of TE was highly related to COVID-19 infections among both sexes. However, the incidence was greater among the female population. The awareness level toward post-COVID-19 TE was poor among most of the participants in our study.PMID:37667959 | DOI:10.26355/eurrev_202308_33437
Source: European Review for Medical and Pharmacological Sciences - September 5, 2023 Category: Drugs & Pharmacology Authors: A Aldahish R Vasudevan H Salem A Alqahtani S AlQasim A Alqhatani M Al Shahrani L Al Mohsen M Hajla D Calina J Sharifi-Rad Source Type: research
Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis
ConclusionThe seroconversion rate in LTR vaccinated with at least two doses of mRNA COVID-19 vaccine could be significantly affected by the vaccine type, immunosuppressant used, BMI, leukopenia, associated comorbidities, and time since transplantation. Nevertheless, booster doses are still recommended for LTR.
Source: Frontiers in Immunology - September 5, 2023 Category: Allergy & Immunology Source Type: research
Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort
EClinicalMedicine. 2023 Jul 21;62:102107. doi: 10.1016/j.eclinm.2023.102107. eCollection 2023 Aug.ABSTRACTBACKGROUND: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs.METHODS: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant o...
Source: Cell Research - September 1, 2023 Category: Cytology Authors: Elisa Gentilotti Anna G órska Adriana Tami Roy Gusinow Massimo Mirandola Jes ús Rodríguez Baño Zaira R Palacios Baena Elisa Rossi Jan Hasenauer Iris Lopes-Rafegas Elda Righi Natascia Caroccia Salvatore Cataudella Zeno Pasquini Thomas Osmo Lidia Del Pi Source Type: research
Common Characteristics of Shoulder Injury Related to Vaccine Administration (SIRVA) Following COVID-19 Vaccination: A Comprehensive Systematic Review
The pathogenesis of SIRVA is incompletely understood, but it is postulated to be an immune-mediated inflammatory response to a vaccine antigen, leading to shoulder pain and dysfunction. The purpose of this investigation is to systematically review the literature related to SIRVA specifically after the COVID-19 vaccination by describing the diagnostic and clinical characteristics, diagnoses associated with SIRVA, and incidence between vaccine types.
Source: Journal of Shoulder and Elbow Surgery - September 1, 2023 Category: Orthopaedics Authors: Luc M. Fortier, Kira L. Smith, Jason G. Ina, Margaret A. Sinkler, Jacob G. Calcei, Michael J. Salata, Robert Gillespie, James E. Voos Tags: Review Article Source Type: research
Long COVID Recovery Remains Rare. Doctors Are Struggling to Understand Why
Since August 2020, David Putrino, director of rehabilitation innovation at New York’s Mount Sinai Health System, has helped treat more than 3,000 people with Long COVID. These patients, in his experience, fit into one of three groups.
[time-brightcove not-tgx=”true”]
A small number, no more than 10%, have stubborn symptoms that don’t get better, no matter what Putrino and his team try. A big chunk see some improvement, but remain sick. And about 15% to 20% report full recovery—an elusive benchmark that Putrino greets with cautious optimism.
“I call it ‘fully recovered for n...
Source: TIME: Health - August 29, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Viruses, Vol. 15, Pages 1828: Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18 & ndash;60 and 60+ Age Cohorts
In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels.
Source: Viruses - August 29, 2023 Category: Virology Authors: Ilya V. Gordeychuk Liubov I. Kozlovskaya Aleksandra A. Siniugina Nadezhda V. Yagovkina Vladimir I. Kuzubov Konstantin A. Zakharov Viktor P. Volok Maria S. Dodina Larissa V. Gmyl Natalya A. Korotina Rostislav D. Theodorovich Yulia I. Ulitina Dmitry I. Vovk Tags: Article Source Type: research
The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers
CONCLUSIONS: The prevalence of SIRVA is estimated at 3% in the adult working population. Signs and symptoms of SIRVA are variable in severity, localization and timing. Soft-tissue abnormalities is the most common clinical sign. This study contributes to clinician's knowledge on SIRVA, aiding in early recognition and treatment, which are imperative for prevention of persistent and severe shoulder pathology.PMID:37635003 | DOI:10.1016/j.vaccine.2023.08.043
Source: Vaccine - August 27, 2023 Category: Allergy & Immunology Authors: Esther R C Janssen Astrid Z van Montfoort Freek Hollman Frederik O Lambers Heerspink Source Type: research
